View More Recent Stories

Jan 21, 2025 09:00AM Amylyx Pharmaceuticals (AMLX) Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Trial
Jan 10, 2025 08:27AM Amylyx Pharmaceuticals (AMLX) Announces Pricing of Public Offering of Common Stock
Dec 6, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
Dec 4, 2024 07:32AM Amylyx Pharmaceuticals (AMLX) Announces Pivotal Phase 3 LUCIDITY Trial Design for Avexitide
Nov 21, 2024 05:09AM Goldman Sachs Reiterates Neutral Rating on Amylyx Pharmaceuticals inc. (AMLX)
Nov 18, 2024 03:31AM Baird Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Outperform
Nov 7, 2024 07:02AM Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q3 EPS by 37c
Oct 23, 2024 06:10AM BofA Securities Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Buy
Oct 18, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
Oct 18, 2024 05:46AM Leerink Partners Reiterates Market Perform Rating on Amylyx Pharmaceuticals inc. (AMLX)
Oct 17, 2024 09:01AM Amylyx Pharmaceuticals (AMLX) Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
Aug 8, 2024 07:00AM Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q2 EPS by 34c
Jul 11, 2024 10:30AM H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
Jul 10, 2024 07:00AM Amylyx Pharmaceuticals (AMLX) Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
Jun 24, 2024 06:36AM H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
View More Recent Stories